Alvotech P/CF

Mitä Alvotech tekee? Alvotech SA, listed on the stock market with ticker ALVO and ISIN LU2458332611, is a biotechnology company headquartered in Luxembourg. The company, which went public in November 2020, employs approximately 1,500 people. Alvotech focuses on the development and manufacturing of biosimilar medicines, aiming to provide affordable treatment options globally. Its pipeline includes eight biosimilar candidates targeting various therapeutic areas such as inflammatory diseases, oncology, and ophthalmology. Specific products in development include AVT02, a biosimilar to Humira (adalimumab), and AVT04, a biosimilar candidate to Stelara (ustekinumab). The company has established strategic commercial partnerships to expand its global reach, leveraging expertise in key markets including the United States, Europe, Japan, China, and regions across South America, Africa, and the Middle East. Alvotech's approach emphasizes the creation of high-quality biosimilars to address unmet medical needs in multiple disease areas. The company operates within the healthcare sector, specifically in biotechnology, and has positioned itself as a key player in the biosimilars market. With a focus on monoclonal antibodies, Alvotech aims to deliver innovative therapies that are both effective and cost-efficient for patients worldwide. Alvotech on yksi Eurpooliin suosituimmista yhtiöistä.